The present application seeks two years of funding to complete COMBINE and its ancillary cost-effectiveness and genetic predictors of treatment response studies. The COMBINE study was initiated in 1997 to answer questions about the benefits of combining behavioral and pharmacological interventions. Two medications, naltrexone and acamprosate, have shown promise in reducing relapse to heavy drinking and improving abstinence in a number of U.S. and European clinical trials. The two behavioral treatments, Medical Management (MM) and Combined BehavioraI Intervention (CBI), have potential to be valuable adjuncts to pharmacotherapy. MM appears to be cost-effective and suitable for delivery in primary care or managed care settings by non-specialists. The primary hypothesis is that combining the two medications (naltrexone and acamprosate) with a moderate intensity behavioral treatment (CBI) will yield better outcomes than less intensive approaches (e.g., placebo and MM; acamprosate or naltrexone and MM) for alcohol dependent patients. A total of 1375 subjects from 11 clinical sites comprise the targeted sample. Individuals meeting study criteria have been randomly assigned to one of nine pharmacological (naltrexone and acamprosate) and behavioral treatment (MM and CBI) combinations to form a complete 2X2X2 factorial design. A ninth cell was later included to test the efficacy of CBI without """"""""pills."""""""" Much has been accomplished since COMBINE's initiation. Over 70% of the intended sample has been randomized to the study treatments, reflecting gender, ethnic, geographic, and clinical diversity. Drinking assessment interviews have been completed for 84% clients at the 16-week follow-up. Two major pilot studies were successfully completed and the findings have been disseminated at conferences and in publications. The requested two-year extension will allow for the recruitment, treatment, and follow-up of the remaining participants, and allow sufficient time for data analysis and manuscript preparation. Results from the COMBINE study are expected to have a major impact on the alcohol treatment delivery system. A common protocol across each of the study sites is submitted. This reflects the cooperative process that has guided the study's efforts across the first five years of operation. However, each study site has provided site-specific information on the budget, budget justifications, listing of key personnel, consultant/consortium agreements, and human subjects sections of their respective proposals.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10AA011776-08
Application #
6684923
Study Section
Special Emphasis Panel (ZAA1-BB (10))
Program Officer
Litten, Raye Z
Project Start
1997-09-30
Project End
2005-08-31
Budget Start
2003-09-15
Budget End
2004-08-31
Support Year
8
Fiscal Year
2003
Total Cost
$445,294
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Psychiatry
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Seneviratne, Chamindi; Franklin, Jason; Beckett, Katherine et al. (2013) Association, interaction, and replication analysis of genes encoding serotonin transporter and 5-HT3 receptor subunits A and B in alcohol dependence. Hum Genet 132:1165-76
Doyle, Suzanne R; Donovan, Dennis M; Simpson, Tracy L (2011) Validation of a nine-dimensional measure of drinking motives for use in clinical applications: the desired effects of drinking scale. Addict Behav 36:1052-60
Johnson, Bankole A; Messing, Robert O; Charness, Michael E et al. (2011) Should the reorganization of addiction-related research across all the National Institutes of Health be structural?--The devil is truly in the details. Alcohol Clin Exp Res 35:572-80
Johnson, Bankole A; Ait-Daoud, Nassima; Seneviratne, Chamindi et al. (2011) Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry 168:265-75
Johnson, Bankole A; Ait-Daoud, Nassima (2010) Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des 16:2103-12
Johnson, Bankole A (2010) Medication treatment of different types of alcoholism. Am J Psychiatry 167:630-9
Oroszi, Gabor; Anton, Raymond F; O'Malley, Stephanie et al. (2009) OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res 33:383-93
Seneviratne, Chamindi; Ait-Daoud, Nassima; Ma, Jennie Z et al. (2009) Susceptibility locus in neurokinin-1 receptor gene associated with alcohol dependence. Neuropsychopharmacology 34:2442-9
Seneviratne, Chamindi; Huang, Weihua; Ait-Daoud, Nassima et al. (2009) Characterization of a functional polymorphism in the 3' UTR of SLC6A4 and its association with drinking intensity. Alcohol Clin Exp Res 33:332-9
Doyle, Suzanne R; Donovan, Dennis M (2009) A validation study of the alcohol dependence scale. J Stud Alcohol Drugs 70:689-99

Showing the most recent 10 out of 28 publications